Publication Month: May 2020 | Report Code: TIPRE00002894 | No. of Pages: 228 | Category: Medical Device | Status: Published
Transdermal Drug Delivery System (TDDS) is described as a self-contained or discrete dosage form known as patches or semisolid forms that are applied to the intact skin. There are different types of semisolid forms, such as, creams, ointments, gels, and sprays. Dosage forms are designed to deliver a therapeutically effective amount of drug across a patient’s skin. The transdermal drug delivery system market is expected to witness a huge growth due to increasing prevalence of chronic diseases, growing demand for non-invasive drug delivery devices, and high demand for self-administration of drugs. However, high cost involved in development of drug delivery systems along with drug failure and recalls of transdermal drug delivery systems are likely to restraint the growth of the market during the forecast years.
With the improvements in medical science and definite oral drug delivery technologies, the non-invasive mode of drug delivery system is now prepared to compete with traditional methods of injectable and painful routes of drug delivery. The non-invasive drug delivery systems include drug delivery via oral, topical, transdermal-active (device-aided enhanced penetration), transdermal-passive, trans-ocular membrane, trans-mucosal membrane, and via alveolar membrane from inhaled medication. Transdermal delivery has a range of advantages compared to the oral route. In particular, it is used when there is a significant first-pass effect of the liver that can impulsively metabolize drugs. Transdermal delivery also has advantages over hypodermic injections, which are painful, create dangerous medical waste, and pose the risk of disease transmission by needle re-use, especially in developing countries. Additionally, transdermal systems are non-invasive and can be self-administered. Patient compliance has been found to be much higher when administrated by non-invasive routes due to decreased pain involved in drug delivery. Therefore, these techniques are considered a preferred mode of drug delivery, thereby driving the market growth in the review period.
Based on type, the transdermal drug delivery system market is segmented into transdermal patches and transdermal semisolids. The transdermal patch segment is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and micro needle patches. The transdermal semisolids segment is further sub segmented into gels, ointments, and sprays. The transdermal patches segment held the larger share of the market in 2019, owing to the advantages such as better patient compliance, faster onset of action, and improved permeability and efficacy. Also, the transdermal patches segment is expected to register a higher CAGR in the market during the forecast period. Additionally, growing emphasis on implementation of inorganic strategies to elevate manufacturing capacity is also projected to drive the transdermal patches segment growth. For instance, in August 2019, Canoa Inc. announced its plan to acquire privately-held ProSolus Inc. to accelerate transdermal drug delivery product development. This strategic acquisition will consolidate company’s transdermal drug delivery products manufacturing capacity.
Based on application, the transdermal drug delivery system market is segmented into pain management, central nervous system disorders, hormonal applications, cardiovascular diseases, and other applications. The hormonal applications segment is further sub segmented into transdermal estrogen therapy and testosterone replacement. In 2019, the pain management segment accounted for the largest share of the global transdermal drug delivery system market owing to increasing number of transdermal drug delivery systems for the pain management. Also, pain management segment is estimated to register the highest CAGR in the market during the forecast period.
Based on end user, the transdermal drug delivery system market is further segmented into hospitals and clinics, home care settings, and others. The hospitals and clinics segment held the largest share of the market in 2019, owing to increasing emphasis on adoption of transdermal drug delivery systems in clinics. Hospitals serve a significant role by providing extensive range of medical services to the patient population suffering from wide variety of diseases. This increased the adoption of drug delivery systems in hospitals and clinics.
|Market Size Value in||US$ 6,063.85 Million in 2019|
|Market Size Value by||US$ 8,415.04 Million by 2027|
|Growth rate||CAGR of 4.3% from 2020-2027|
|No. of Pages||228|
|No. of Tables||141|
|No. of Charts & Figures||73|
|Historical data available||Yes|
|Segments covered||Type ; Application ; End User ; and Geography|
|Regional scope||North America, Europe, Asia Pacific, Middle East & Africa, South & Central America|
|Country scope||US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
Product launches and expansion strategy is commonly adopted by companies to expand their footprint worldwide and meet the growing demand. This strategy is most commonly adopted by the market players in order to expand its product portfolio.
The market players operating in the transdermal drug delivery system market adopted the strategy of product innovation to cater to changing customer demand across the world, which also permits the players to maintain their brand name globally.
The List of Companies - Transdermal Drug Delivery Market